Commonwealth Equity Services LLC Sells 6,718 Shares of GSK plc (NYSE:GSK)

Commonwealth Equity Services LLC reduced its stake in GSK plc (NYSE:GSK - Free Report) by 1.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 348,385 shares of the pharmaceutical company's stock after selling 6,718 shares during the period. Commonwealth Equity Services LLC's holdings in GSK were worth $11,782,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GSK. Dorsey & Whitney Trust CO LLC raised its stake in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after buying an additional 278 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Rehmann Capital Advisory Group raised its position in shares of GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock worth $232,000 after purchasing an additional 332 shares during the last quarter. GC Wealth Management RIA LLC boosted its stake in GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after purchasing an additional 353 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its stake in GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after purchasing an additional 389 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Remove Ads

GSK Stock Performance

Shares of GSK stock traded down $0.19 during trading hours on Friday, reaching $39.22. The company had a trading volume of 4,020,576 shares, compared to its average volume of 4,334,257. The firm has a market cap of $81.18 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The business has a fifty day moving average price of $36.66 and a 200-day moving average price of $36.97. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.01%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 98.74%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.